Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0155339 (Brown)
 12,436 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Twenty-two patients (36 eyes) are reported with Brown-McLean syndrome, which consists of peripheral corneal edema associated with peripheral endothelial pigment deposits, usually after intracapsular cataract extraction. This group, the largest reported to date, had a spectrum of corneal alterations, those at the more severe end of the spectrum being both progressive and symptomatic. Some patients required medical and surgical treatment, including keratoplasty. Four corneas (two obtained surgically, two postmortem) were examined by light and electron microscopy (EM). Centrally, the corneas were relatively normal, but peripherally there were disintegrated endothelial cells with an abnormal posterior collagenous layer of Descemet's membrane. Scanning EM showed a somewhat distinct junction between the normal central endothelium and the diseased peripheral endothelium.
Cornea 1992 Nov
PMID:Clinical and pathologic findings of aphakic peripheral corneal edema: Brown-McLean syndrome. 146 22

FK-506 is a new immunosuppressant with the ability to inhibit activation of T-lymphocytes that would be cytolytic to an allograft. We studied periocular injection of FK-506 in a rat penetrating keratoplasty model. Corneas were transplanted from Brown Norway rats into Lewis rat recipients. The transplanted rats received periocular injection of either 0.5 mg/kg FK-506 or an equivalent volume of FK-506 vehicle only. Injections were given 1 day before, at keratoplasty, and every other day after keratoplasty until allograft rejection. The group receiving FK-506 had a significant delay in allograft rejection (p < 0.05). The FK-506 group rejected 12-20 days postkeratoplasty with a mean rejection time (MRT) of 14.3 days, compared with 8-14 days (MRT 11.1 days) for the control group. We conclude that periocular administration of FK-506 is effective in prolonging allograft survival in the rat penetrating keratoplasty model.
Cornea 1993 May
PMID:Periocular FK-506 delays allograft rejection in rat penetrating keratoplasty. 768 63

We tested the ability of 15-deoxyspergualin (DSG), a new immunosuppressant, to inhibit corneal allograft rejection in the rat penetrating keratoplasty model. Fifty-six inbred Lewis rats were recipients of orthotopic corneal allografts from Brown Norway rats. Allogeneic groups received daily intramuscular injections of DSG 2, 3, 4, or 10 mg/kg/day. The animals treated with 2 mg/kg/day had four out of 10 grafts rejected; in the 3 mg/kg/day group none of the six grafts rejected; whereas in the 4 mg/kg/day group one out of 15 grafts rejected. The animals treated with 10 mg/kg/day became emaciated and died during the second and third postoperative weeks with relatively clear grafts. All corneas rejected following discontinuation of the drug. We conclude that the systemic administration of DSG at 3 or 4 mg/kg/day results in effective suppression of corneal allograft rejection in the rat penetrating keratoplasty model.
Cornea 1994 Jan
PMID:Suppression of graft rejection using 15-deoxyspergualin in the allogeneic rat penetrating keratoplasty model. 813 3

Cyclosporin A (CSA) has been shown to prolong corneal allograft survival in a variety of animal models. Misoprostol is a prostaglandin E1 analogue with oral bioavailability and immunosuppressive properties. Misoprostol and CSA are synergistic immunosuppressants in vitro. In the present study, we evaluated the effect of adding misoprostol to a subtherapeutic dose of CSA in the orthotopic allogeneic rat penetrating keratoplasty model. Seventy inbred Lewis rats were recipients of orthotopic corneal allografts from Brown-Norway donors. Ten Lewis rats received orthotopic syngeneic grafts (Lew to Lew). Two separate experiments with 40 animals per trial were performed. In each trial, the rats were divided equally into four groups. Trial A: allogeneic control (A1), syngeneic control (A2), CSA at 10 mg/kg/d (A3), and CSA at 15 mg/kg/d (A4). Trial B: allogeneic control (B1), CSA alone at 7.5 mg/kg/d (B2), misoprostol alone at 1 mg/kg/d (B3), and CSA with misoprostol at 7.5 and 1 mg/kg/d, respectively (B4). Syngeneic control A2 as well as group A4 remained clear through postoperative day 22. The allogeneic control groups A1 and B1, plus treatment groups B2 and B3, rejected their grafts by postoperative day 12. Groups A3 and B4 demonstrated a delay in allograft rejection that continued to be statistically significant through the 12th postoperative day (p < 0.001). We conclude that the addition of systemic misoprostol to CSA can effectively prolong corneal allograft survival in the orthotopic allogeneic rat penetrating keratoplasty model.
Cornea 1996 Jan
PMID:Misoprostol with cyclosporin A prolongs corneal allograft survival in an animal model. 890 85

Massive infiltration of eosinophils is the typical histopathologic feature of severe forms of allergic conjunctival diseases (ACDs) such as vernal keratoconjunctivitis. Although ACD is an antigen (Ag)-specific disease, eosinophils lack Ag-specific receptors. Therefore, my group studied the likely roles of immunocompetent cells bearing Ag-specific receptors in inducing conjunctival eosinophil infiltration in ACDs. To induce experimental conjunctivitis (EC), Brown Norway rats and C57BL/6 and Balb/c mice were passively immunized by the transfer of Ag-specific or primed IgE, splenocytes, or purified T-cells and then challenged with Ag in eyedrops. The transfer of Ag-primed splenocytes or T-cells, but not of Ag-specific IgE, induced conjunctival eosinophil infiltration. We also showed that soon after EC induction by T-cell transfer, activated Ag-specific T-cells infiltrated the conjunctiva. Moreover, when EC-developing animals were topically treated with the T-cell-specific immunosuppressants cyclosporin A and FK506, conjunctival eosinophil infiltration was abrogated. In addition, only the transfer of Ag-specific type 2 helper T-cells (TH2 cells), but not of type 1 helper T-cells or CD8 T-cells, could induce conjunctival eosinophil infiltration. Our data show that Ag-specific TH2 cells play a crucial role in inducing conjunctival eosinophil infiltration during the development of EC. It is necessary to elucidate the roles that conjunctival residential cells and immunocompetent cells other than T-cells play in the conjunctival eosinophil infiltration of EC.
Cornea 2007 Oct
PMID:Roles of T-cells in the development of allergic conjunctival diseases. 1788 14